A big step forward has been made in the battle against Alzheimer's disease. Three new drugs have been given the green light by the FDA. These drugs are aducanumab, lecanemab, and donanemab. They are designed to help people in the early stages of Alzheimer's or those with mild cognitive impairment.
A big change is coming to Europe's healthcare systems. Anti-amyloid antibodies are being looked at for treating Alzheimer's disease. This is a big deal. If approved, it will bring both good things and tough challenges. Experts are stepping in to help figure out how to make this work. Fi
Alzheimer's disease is a complex condition that affects millions of people. At the heart of this disease lies a protein called amyloid beta (Aβ). This protein can take on many forms, and it is not entirely clear which ones are the most harmful. Scientists have found that when brain tissue containing
Alzheimer's disease is a complex condition that scientists are still trying to understand. One big challenge is figuring out how to spot it early. Thanks to modern technology, researchers can now look at the entire human genome using something called microarrays. This should make diagnosing Alzheime
The brain is a complex organ, and its workings are still a mystery in many ways. One area of interest is how finger movements relate to brain structure in people with cognitive issues. This is important because problems with movement often show up before memory issues do. So, researchers decided to
Alzheimer's disease can cause a lot of confusion and fear. One strange thing that happens is that some people with Alzheimer's think that others are stealing from them. This is called theft delusion. Four women with Alzheimer's were studied to understand this better. They all lived alone and had
Graphene is a superstar in the world of biosensors. This 2D wonder material is making waves due to its unique structure and electrical properties. It allows for the detection of various biological targets without needing labels or amplification. This makes it highly sensitive and selective. However,
Alzheimer's disease is a growing concern, with millions of people affected worldwide. Early detection is crucial for better management and treatment. Two important indicators of this disease are monoamine oxidase B (MAO-B) and acetylcholinesterase (AChE). These substances are often elevated in indiv
Two new drugs, lecanemab and donanemab, have hit the market. They are designed to tackle Alzheimer's disease. They work by targeting and removing beta-amyloid protein from the brain. This protein is a key player in the development of Alzheimer's. The drugs have shown some promising results in cl
Alzheimer's disease is a big deal. It's a condition where the brain slowly breaks down. It's one of the toughest medical puzzles out there. Scientists have found that certain gene mutations can lead to early-onset Alzheimer's. These mutations are in the presenilin 1 and 2 (PSEN1 and PSEN2) and the a
